Eyal Rubin
2022
In 2022, Eyal Rubin earned a total compensation of $1.1M as Senior Vice President, Chief Financial Officer at Protalix BioTherapeutics, a 26% increase compared to previous year.
Compensation breakdown
| Bonus | $397,678 |
|---|---|
| Option Awards | $75,889 |
| Salary | $312,515 |
| Stock Awards | $168,667 |
| Other | $103,532 |
| Total | $1,058,281 |
Rubin received $397.7K in bonus, accounting for 38% of the total pay in 2022.
Rubin also received $75.9K in option awards, $312.5K in salary, $168.7K in stock awards and $103.5K in other compensation.
Rankings
In 2022, Eyal Rubin's compensation ranked 2,910th out of 5,756 executives tracked by ExecPay. In other words, Rubin earned more than 49.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,910 out of 5,756 | 49th |
Division Manufacturing | 1,628 out of 3,133 | 48th |
Major group Chemicals And Allied Products | 759 out of 1,419 | 47th |
Industry group Drugs | 708 out of 1,320 | 46th |
Industry Biological Products, Except Diagnostic Substances | 171 out of 291 | 41st |
Source: SEC filing on May 18, 2023.
Rubin's colleagues
We found two more compensation records of executives who worked with Eyal Rubin at Protalix BioTherapeutics in 2022.
News
Protalix BioTherapeutics CEO Dror Bashan's 2023 pay jumps 83% to $2.7M
April 29, 2024
Protalix BioTherapeutics CEO Dror Bashan's 2022 pay jumps 27% to $1.5M
May 18, 2023
Protalix BioTherapeutics CEO Dror Bashan's 2021 pay slips 14% to $1.2M
April 29, 2022
Protalix BioTherapeutics CEO Moshe Manor's 2019 pay slips 14% to $616K
April 15, 2020